Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 1 of 51 
 TITLE PAGE  
 
Protocol Title:   
Evaluating the efficacy and comfort of the PureWick ™ Male E xternal Catheter against a 
Comparator in Healthy Volunteers   
 
Protocol Number:  UCC -23AC022   
Version Number: 1.0  
Study Device: BD PureWick ™ Male External Cath eter (PWM030)  
Study Type: Post-Market  
Short Title:  MECCE (Male External Catheters’ Comparison of Comfort & Efficacy ) 
Sponsor Name: [CONTACT_833807] , Dickinson and Company  
Legal Registered Address:  
Becton, Dickinson and Company  
[ADDRESS_1157948]:  
Ajesh Raju  
Clinical Project Manger  
[EMAIL_15846]   
 
Regulatory Agency Identifier Number(s) : NCT number TBD  
National Principal Investigator:   [INVESTIGATOR_833771]  
1.0 TBD  Original  
  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 2 of 51 
  
SPONSOR PROTOCOL APPROVAL   
 
Signature [CONTACT_225456].  
Individual or 
function  Name  [CONTACT_833808] – Quality 
Engineering  Michael Wolfe  This document is 
signed 
electronically in the 
eTMF system   
 
  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157949] sign the Clinical 
Study Agreement (CSA) and obtain written approval from the appropriate Institutional 
Review Board (IRB)/Ethics Committee (EC).  
2. The Investigator must receive BD -sponsored training prior to site activation. The 
Investigator is responsible for ensuring that all Sub -Investigators and clinical staff are 
adequately trained prior to performing any data collection or study -related procedu res.   
3. The Principal Investigator [INVESTIGATOR_695343], any modifications as requested by [CONTACT_1201]/EC, the signed CSA, the 
ethical principles of the Declaration of Helsinki, Good Clinical Practice (I CH E6) / ISO 
[ZIP_CODE]), and applicable national/regional regulations and laws.  
4. If applicable, ensure that written informed consent is obtained from each participant prior 
to the conduct of any study procedure, using the current IRB/EC approved Informed 
Consent Form.  
 
I have read and understand the contents of this  study protocol. I agree to follow and abide by [CONTACT_270872]. I agree to conduct the  trial in accordance with 
the study  protocol,  the signed Clinical Study Agreeme nt, and Good Clinical Practice (GCP) as 
well as applicable FDA and ISO regulations (e.g.,  21 CFR Parts  812, 50, 54, 56; ISO [ZIP_CODE]). I 
agree to participate in  BD-Sponsored training prior to performing any data collection or  study -
related procedures.  
 
 
Agree d to by (Investigator):   
  
_______________________________________________   
Printed Name – Investigator    
  
_______________________________________________   
Signature – Investigator   
 
_______________________________________________   
 Site Number  
 
_________ ______________________________________   
Date    UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 4 of 51 
  
 
TITLE PAGE  ................................ ................................ ................................ ................................ .. 1 
Abbreviations  ................................ ................................ ................................ ................................ .. 8 
1 PROTOCOL SUMMA RY ................................ ................................ ................................ ...... 9 
1.1 Synopsis  ................................ ................................ ................................ ...........................  9 
1.2 Schema  ................................ ................................ ................................ ...........................  15 
2 INTRODUCTION  ................................ ................................ ................................ ................  16 
2.1 Background  ................................ ................................ ................................ ....................  16 
2.2 Rationale ................................ ................................ ................................ .........................  17 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................  17 
2.3.1  Risk Assessment  ................................ ................................ ................................ ..... 17 
2.3.2  Benefit Assessment  ................................ ................................ ................................ . 19 
2.3.3  Overall Benefit: Risk Conclusion  ................................ ................................ ...........  20 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ......................  20 
4 STUDY DESIGN ................................ ................................ ................................ ..................  20 
4.1 Overall De sign................................ ................................ ................................ ................  20 
4.2 Scientific Rationale for Study Design  ................................ ................................ ............  22 
4.2.1  Participant Input into Design  ................................ ................................ ..................  23 
4.3 End of Study Definition  ................................ ................................ ................................ . 23 
5 STUDY POPULATION  ................................ ................................ ................................ ....... 23 
5.1 Inclusion Criteria  ................................ ................................ ................................ ............  23 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...........  24 
5.3 Lifestyle Considerations  ................................ ................................ ................................ . 24 
5.4 Screen Failures  ................................ ................................ ................................ ...............  24 
6 STUDY INTERVENTION(S)  ................................ ................................ ..............................  24 
6.1 Investigational/Test Device  ................................ ................................ ............................  24 
6.2 Control Device/Standard of Care  ................................ ................................ ...................  24 
6.3 Ancillary Devices/Products  ................................ ................................ ............................  25 
6.4 Device Labeling  ................................ ................................ ................................ .............  25 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 5 of 51 
 6.5 Treatment Allocation and Measures to Minimize Bias  ................................ ..................  25 
6.5.1  Randomization  ................................ ................................ ................................ ........  25 
6.5.2  Blinding/Masking  ................................ ................................ ................................ ... [ADDRESS_1157950] Preparation – Prior to Arrival at Site  ................................ ................................ . 27 
7.2 Screening and Enrollment  ................................ ................................ ..............................  27 
7.3 Medical History / Baseline Assessments  ................................ ................................ ....... [ADDRESS_1157951] Procedure  ................................ ................................ ................................ ................  28 
8 PARTICIPANT DISCONTINUATION/WITHDRAWAL ................................ ..................  29 
8.1 Discontinuation/Withdrawal  ................................ ................................ ..........................  [ADDRESS_1157952] to Follow -Up ................................ ................................ ................................ ..........  29 
9 ADVERSE EVENTS AND DEVICE DEFICIENCIES  ................................ ......................  29 
9.1 Definitions of Events  ................................ ................................ ................................ ...... 30 
9.1.1 Adverse Events (AEs)  ................................ ................................ .............................  30 
9.1.2  Serious Adverse Events (SAEs) ................................ ................................ ..............  [ADDRESS_1157953] (ADE) / Serious Adverse Device Effect (SADE)  ..............  30 
9.1.4  Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  ........................  31 
9.2 Severity of Adverse Events  ................................ ................................ ............................  31 
9.3 Relationship of Adverse Event to Device(s)/Procedure  ................................ .................  32 
9.4 Reporting of Events  ................................ ................................ ................................ ........  32 
9.5 Safety Committees  ................................ ................................ ................................ .........  33 
9.6 Device Deficiencies ................................ ................................ ................................ ........  33 
10 STATISTICAL METHODS  ................................ ................................ ................................ . 34 
10.1  Overview of Study Design  ................................ ................................ .............................  34 
10.2  Sample Size Considerations  ................................ ................................ ...........................  34 
10.3  Analysis Population ................................ ................................ ................................ ........  34 
10.4  General Considerations  ................................ ................................ ................................ .. 35 
10.4.1  Handling of Missing Data  ................................ ................................ .......................  35 
10.4.2  Covariates  ................................ ................................ ................................ ...............  35 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 6 of 51 
 10.4.3  Multiplicity Control  ................................ ................................ ................................  35 
10.5  Primary Endpoint(s)  ................................ ................................ ................................ ....... 35 
10.6  Secondary Endpoint(s)  ................................ ................................ ................................ ... [ADDRESS_1157954] Retention  ................................ ................................ ................................ ............  37 
12 QUALITY CONTROL AND ASSURANCE  ................................ ................................ ...... 38 
12.1  Control of Study Products  ................................ ................................ ..............................  38 
12.2  Monitoring  ................................ ................................ ................................ ......................  38 
12.3  Audits and Inspections  ................................ ................................ ................................ ... 39 
12.4  Protocol Deviations  ................................ ................................ ................................ ........  40 
13 ADMINISTRATIVE REQUIREMENTS  ................................ ................................ ............  40 
13.1  Investigator and Site Selection  ................................ ................................ .......................  40 
13.2  Training  ................................ ................................ ................................ ..........................  41 
13.3  Required Documents  ................................ ................................ ................................ ...... 41 
13.4  Publication Policy  ................................ ................................ ................................ ..........  41 
13.5  Study Registration  ................................ ................................ ................................ ..........  42 
13.6  Termination of Study  ................................ ................................ ................................ ..... 42 
14 ETHICAL AND REGULATORY CONSIDERATIONS  ................................ ....................  42 
14.1  IRB/EC Approval  ................................ ................................ ................................ ...........  43 
14.2  Informed Consent and Confidentiality  ................................ ................................ ...........  43 
14.2.1  Confidentiality  ................................ ................................ ................................ ........  43 
14.3  Regulatory Status  ................................ ................................ ................................ ...........  44 
14.4  Statement of Compliance  ................................ ................................ ...............................  44 
15 REFERENCES  ................................ ................................ ................................ .....................  45 
16 APPENDICES  ................................ ................................ ................................ ......................  46 
16.1  Appendix 1: PureWick™ Male External Catheter Instructions for Use (IFU)  ..............  46 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 7 of 51 
 16.2  Appendix 2: Sage PrimoFit™ Instructions for Use (IFU)  ................................ .............  48 
16.3  Appendix 3: Participant Comfort Scale Survey  ................................ .............................  50 
16.4  Appendix 4: Professional Ease of Use Questionnaire  ................................ ....................  51 
 
  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157955], Inc.  
BD Becton Dickinson and Company  
BMI  Body Mass Index  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CRF  Case Report/Record Form  
CRO  Contract Research Organization  
EDC  Electronic Data Capture  
FDA  Food and Drug Administration  
FDAAA  FDA Amendments Act of  [ADDRESS_1157956]  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IFU Instructions for use  
IRB/EC  Institutional or Independent Review Board/Ethics Committee  
MEC  Male external catheter  
SAE  Serious Adverse Event  
SD Standard Deviation  
SoA Schedule of Activities  
SOP Standard Operating Procedure  
TMF  Trial Master File  
WHO  World Health Organization  
  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 9 of 51 
  
1 PROTOCOL SUMMARY  
 
1.1 Synopsis  
 
Protocol Title  Evaluating the efficacy and comfort of the PureWick ™ male external 
catheter against a comparator in Healthy Volunteers  
Short Title  MECCE (Male External Catheters’  Comparison of  Comfort & Efficacy)  
Rationale  The purpose of this study is to provide clinical evidence to compare the  
effectiveness and comfort of PureWick™ Male  against a comparator  for 
non-invasive urine output management in patients with varying male 
anatomy.  
Objectives and Endpoints  
 Objective(s ) Endpoint(s)  
Primary  
• To assess the 
performance of the 
PureWick™  Male 
(System) against an 
established comparator 
(Stryker/ Sage 
PrimoFit™ ) Primary  
• Capture rate following void 
(captured as % of urine 
captured by [CONTACT_833784], 
measured by [CONTACT_8497])  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 10 of 51 
 Protocol Title  Evaluating the efficacy and comfort of the PureWick ™ male external 
catheter against a comparator in Healthy Volunteers  
Secondary  Objective (with 
Hypothesis Test):  
• To assess the 
performance of the 
PureWick™  Male 
(System) in patients that 
are unable to use 
traditional sheath style 
condom catheters.   
 
Secondary Objective (without 
Hypothesis test):  
• To assess participant 
comfort  after using the 
MEC  
 
• To assess ease of use by 
[CONTACT_833785]  
• Capture rate following void 
(captured as % of urine 
captured by [CONTACT_833784], 
measured by [CONTACT_8497]).  
 
 
 
 
• Overall Comfort score on a 
5-point Likert scale (brief 
questionnaire)  
 
• Ease of use score on a 5 -
point Likert scale (brief 
questionnaire)  
Design and Overview  This is a Prospective, Randomized, Crossover, Single -blind , Single 
Center Healthy Volunteer Study conducted over 1 day, with 2 voids 
using the PW Male external catheter vs. comparator Sage PrimoFit™ . 
This study is designed to assess the performance, comfort , and ease of 
use of the PW Male external catheter  as com pared to the comparator  
product .  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 11 of 51 
 Protocol Title  Evaluating the efficacy and comfort of the PureWick ™ male external 
catheter against a comparator in Healthy Volunteers  
Study Device  Test product(s):   BD PureWick ™ Male (PWM030)  
The PureWick™ Male External Catheter  (MEC)  is intended for non -
invasive urine output management in male patients.  The PureWick™ 
Male External Catheter is a commercially available device  which is 
Class I, 510(K) e xempt . 
Reference/Comparator product(s):  Sage PrimoFit™  (5404)  
The Sage PrimoFit™  is a commercially available device  which is Class 
I, 510(K) exempt . 
Ancillary Product(s):  
• Standard suction tubing and cannister  
• BBS Revolution: Bladder Scanner + Display (PD0100002)  
• Absorbent under -pads 
• Commercially available scales  
• Clippers/trimmers  
• Wipes/towels for peri -care 
• Turning wedge (45 -degree foam wedge)  
• PPE UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 12 of 51 
 Protocol Title  Evaluating the efficacy and comfort of the PureWick ™ male external 
catheter against a comparator in Healthy Volunteers  
Participants  Adult male healthy volunteers  with a target of 50% of subjects in each 
of the following cohorts:  
o Cohort A: Non morbidly obese men: BMI < 40  
o Cohort B: Morbidly Obese men: BMI ≥40  
o  
Inclusion Criteria:  
 
• Adult  Male  Patients >18 years old  
• Male anatomy at time of enrollment   
• Ability to speak and understand English  
• Willing to comply with all study procedures in this protocol  
• Able to independently void urine  
• Provision of signed and dated informed consent form  
 
Exclusion Criteria:  
 
• Urinary incontinence which  does not allow the subject to 
spontaneously void  
• Frequent epi[INVESTIGATOR_833772]  
• Has Urinary Retention  
• Has any irritation, wound, open lesion , at the application site,  on 
the genitalia, perineum, or sacrum  
• Recent surgery of the external urogenital  tract, penis, or pubic 
area 
• Not able to comply with study procedures independently 
without required assistance  
• Any other condition that, in the opi[INVESTIGATOR_871], 
would preclude them from participating in the study  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 13 of 51 
 Intervention(s)/Procedure(s)  Prior to arrival, participants will be instructed to consume fluids and to 
come to the test site with a full bladder. Upon arrival at the test site, 
participants will be consented and screened against inclusion/exclusion 
criteria. Those meeting eligibility  criteria will be assigned a treatment 
order. Participants will be divided into two cohorts .  
Cohort A: Non morbidly  obese men: BMI <40 
Cohort B: Morbidly obese men: BMI ≥[ADDRESS_1157957] area, instructed to undress, and put 
on a gown. The Health Care Professional (HCP) will complete a visual 
assessment of the participant’s pubic/ genital region to ensure that the 
participant is trimmed and assess the  anatomy . Trimmers can be 
provided if the participant did not arrive to the site trimmed. The HCP 
will then assess  for a buried penis and/or anatomical compatibility with 
traditional sheath style condom catheters for each participant.  “A buried 
penis refer s to a normal -sized phallus encompassed by [CONTACT_833786], 
subcutaneous tissue, and/or fat in the prepubic area” causing a reduced 
visible and/or functional length of the phallus.11 
Void 1:  
The bed in  the test area will be set with a pre -weighed absorbent pad  and 
a pre -weighed urine collection canister  (with the lid) .  Once the 
participant feels the need to void, t he Health Care Professional ( HCP ) 
will place either the PureWick ™ MEC  (Device A)  or the Sage 
PrimoFit™  (Device  B) (depending on randomized treatment  order) 
according to the device instructions  for use ( IFU) and confirm the 
correct placement prior to the voiding epi[INVESTIGATOR_1865]. The participant will be 
placed in a semi -fowler position (head of bed elevated approximately 30 
degrees) in a hospi[INVESTIGATOR_833773] a turning wedge 
prior to the voiding epi[INVESTIGATOR_1865].  Participants will be monitored for 
approximately 2 hours from the time of the device application, through 
one void. (The skin needs to be assessed at least every two hours while 
wearing a MEC .) After the void, the pre -weighed absorbent pad and 
urine collection canister will be weighed  (with the lid ), and weights 
documented in the source. The Pure Wick MEC or Sage PrimoFit™  will 
be removed by [CONTACT_82275]. After removal, the HCP will note any signs of 
irritation/injury in the perineal area. Any unresolved erythema (redness), 
erythema (swelling), bleeding, injury, or rash should be recorded as an 
Adverse Event.  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 14 of 51 
 Protocol Title  Evaluating the efficacy and comfort of the PureWick ™ male external 
catheter against a comparator in Healthy Volunteers  
The participant will be asked to complete a brief survey to assess device 
comfort  immediate ly after the completed void . 
The HCP will be asked to complete a brief survey to assess device ease 
of use for the participant just treated.  
Void 2 :   
Participants will be asked to not void and to drink approximately 16 
fluid ounces of liquid. When the participant feels the need to void  (a 
second time) , the HCP will confirm via bladder scanning  procedure that 
the bladder volume is ≥125mL If the volume is determined to be 
inadequate, the participant will be asked  if they can wait to void , drink 
additional  fluids as tolerated and  be re-assessed in approximately 30 
minutes. If the participant does not feel comfortable waiting to void, 
they will be allowed to proceed with void 2.  
Void 2 will be repeated per the Void 1 procedure using the 2nd device 
assigned p er randomization.  
The participant will complete a brief survey (for the second device 
sequence) immediately following the void  to assess device comfort and 
will then be discharged from the study.  
The HCP will complete a brief survey to assess device ea se of use  for 
the participant just treated . 
Investigational Sites  [ADDRESS_1157958]-Market    
The investigation will use both the PureWick™ Male  External Catheter  
and Sage PrimoFit™  for its intended purpose.  
 
 
 
 
 
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 15 of 51 
  
 
 
1.2 Schema  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Screening and  
Enrollment  Obtain informed consent. Screen potential participants by [CONTACT_21198], 
obtain history, document.   
Randomize (Sequence 1 or Sequence 2)  
Void #[ADDRESS_1157959] either the Pure Wick MEC (Device A) or the Sage Primo Fit (Device B) 
(depending on randomized sequence order) according to the device instructions for use (IFU) 
and confirm the correct placement prior to the voiding epis ode. The HCP will remove the 
device once void is completed.  
Participant 
Questionnaire  The participant will be asked to complete a brief survey to assess device comfort.  
Void #[ADDRESS_1157960] area, instructed to undress, and put on a gown. The 
Health Care Professional (HCP) will complete a visual assessment of the participant’s pubic/ 
genital region to ensure that the participant is trimmed and assess the  anatomy. Trimmers can 
be provided if the participant did not arrive to the site trimmed. The HCP will then assess for 
a buried penis and/or anatomical compatibility with traditional sheath style condom catheters 
for each participant.  Randomiz ation  
HCP Assessment  
The HCP will be asked to complete a brief survey  to assess device ease of use.  HCP 
Questionnaire  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 16 of 51 
  
 
2 INTRODUCTION  
The PureWick™ MEC is intended for non -invasive urine output management in male 
patients. The PureWick™ MEC is a single use nonsterile device. It is composed of the 
following elements: a flexible polyurethane shell, a patient -contact[CONTACT_833787] [ADDRESS_1157961] hospi[INVESTIGATOR_833774], and vents to allow for air intake. To 
capture voided urine, the catheter is connected to a wall vacuum system.  This vacuum 
(not felt by [CONTACT_28024]) is intended to pull urine through the catheter, regardless of the urine 
flow rate. Urine continues quic kly through vinyl tubing until it reaches a collection 
canister, away from the body.  
The PureWick™ MEC does  not require a doctor’s order , is a commercially available and 
marketed device commonly used in the hospi[INVESTIGATOR_6885], and is an FDA 510(k) Exempt, 
Class I device.  See Appendix  1 for the Instructions for Use (IFU).  
 
2.1 Background  
Urinary incontinence increases the risk for complications such as incontinence -associated 
dermatitis (IAD) and  pressure ulcers1-4, and treatment can be difficult, time -consuming, 
and costly4. Prolonged usage of an indwelling Foley catheter is a well -known risk factor 
for the development of catheter -associated urinary tract infections (CAUTI).  The 
consequences of urinary tract infections (UTIs) can be serious as they have been found to 
increase mortality5,6, prolong hospi[INVESTIGATOR_059], and increase readmissions5.  UTIs are a 
leading cause of the development of bloodstream infections (BSIs) and sepsis, and the 
most severe infections are associated with increased morbidity, mortality, and costs.[ADDRESS_1157962] be used.  However, managi ng urine 
output without an indwelling catheter has been challenging given the limited device 
options recently available.  
For male patients, condom catheters are an option for external drainage that may allow 
for accurate urine output measurements and/or m anagement of urinary incontinence. 
However, there are several disadvantages and challenges associated with sheath -style 
condom catheter types of devices.  First, appropriate sizing of condom catheters may be 
difficult; too large catheters may simply slip o ff the penis while too small catheters may 
cause pressure -associated tissue trauma.7 Second, adhesives used to hold the catheter UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157963] may fail; too little adhesion causes sheath slippage while too strong 
adhesion may lead to skin damage when the  sheath is removed.7 Lastly, condom catheters 
can only be used for males with normal anatomy and cannot be used with men with 
buried/hidden penis. “A buried penis refers to a normal -sized phallus encompassed by 
[CONTACT_833786], subcutaneous tissue, and/or fat in the prepubic area” causing a reduced visible 
and/or functional length of the phallus11; buried penis  is an acquired deformity secondary 
to obesity8,9. Obesity is increasing in our society, with a prevalence of up to 40.8% in 
middle -aged men.[ADDRESS_1157964] spacing and generalized gross edema. Although no 
published data are available that could be found regarding the specific incidence of the 
hidden penis in morbidly ob ese men, acquired buried penis is increasing in incidence in 
adult men as morbid obesity becomes more prevalent.10 
The PureWick™ Male External Catheter (MEC) is a new external drainage device to 
address the need for an effective, non -invasive method of man aging urine output in male 
patients .   
 
2.2 Rationale  
The purpose of this study is to provide clinical evidence to compare the effectiveness and 
comfort of PureWick™ Male against a comparator for non -invasive urine output 
management in patients with varying male anatom y. Specifically, t he study will collect 
data about how the male external catheters perform when participants are positioned on 
their side using a turning wedge with the head of the bed elevated , mimicking common 
patient position ing in the hospit al setting.  
 
2.3 Risk/Benefit Assessment  
Participants in this study will be treated with approved, marketed devices and will use the 
investigational devices as intended. Therefore, participants will be exposed to the same 
risks shared by [CONTACT_833788] a real -
world setting. More detailed information about the known and expected benefits and risks 
and reasonably expected adverse events of the PureWick™ MEC  and the Sage 
PrimoFit™  may be found in the Instructions f or Use of each product.  
 
 
2.3.1 Risk Assessment  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 18 of 51 
 Potential Risk of Clinical 
Significance  Summary of Data/Rationale 
for Risk  Mitigation Strategy  
Study Intervention : PureWick™ Male External Catheter  
Potential adverse events:  
 
• Skin injury  
• Skin irritation  
• Allergic reaction  
 
 
 PureWick™ MEC is an 
external device placed around 
the base of the penis and 
adhered to the pelvic skin . • To avoid potential 
skin injury, never pull 
the device directly 
away from the patient. 
Always peel in the 
direction from head to 
foot. 
• Perform perineal care  
using the included 
wipes and assess skin 
integrity  before device 
application.  
• Assess the device 
placement and 
patient’s skin at least 
every 2 hours.  
• Monitor for pulling 
and tension on the 
device after turning 
the patient.  
• Replace the device 
every 24 hours  or if 
soiled with feces, 
blood, or semen.  
• Remove the device 
prior to ambulation.  
Study Intervention: Sage PrimoFit™  
Potential adverse events:  
 
• Skin injury  
• Skin irritation  
 Sage PrimoFit™  is an 
external urine management 
device for the male anatomy  
that adheres to the pelvic and 
abdominal skin.  • Clean, prep,  and dry 
patient’s genital area 
before device 
application  
• Perform skin 
assessment every 2 
hours  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 19 of 51 
 Potential Risk of Clinical 
Significance  Summary of Data/Rationale 
for Risk  Mitigation Strategy  
• Assess device 
periodically to ensure 
proper placement, 
particularly after 
turning or 
repositioning patient.  
• Device can be left on 
skin for up to [ADDRESS_1157965] device 
if soiled with stool or 
bodily fluids other 
than urine . 
• Discontinue use 
during patient 
ambulation . 
Study Procedures  
Discomfort due to full 
bladder  Participants will be asked to 
refrain from voiding until 
bladder volume reaches 
>125mL  to ensure a full 
second void.  • Participants who meet 
the eligibility criteria 
and follow study 
instructions should 
not have a bladder 
that is uncomfortably 
full. 
   
2.3.2 Benefit Assessment  
This is a healthy volunteer study in which the participants are not known to suffer 
from any of the conditions/indications for use of the PureWick™ MEC or Sage 
PrimoFit™ . As such, there is likely to be no direct benefit for study participants. 
Data gathere d through this study could benefit future patients utilizing the study 
devices.  Study participants may contribute to the process of generating clinical 
evidence for urine output management  in male patients .  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 20 of 51 
 2.3.3 Overall Benefit: Risk Conclusion  
Taking into consideration the measures to minimize risk to participants i n this 
study, the potential risks identified in association with both the PureWick™ Male 
External Catheter and the Sage PrimoFit™  are minimal . Both products are 
commercially available for use. This  is a post -market , non-significant risk  study .  
 
3 OBJECTIVES  AND ENDPOINTS  
 
 
Objectives  Endpoints  
Primary   
• To assess the performance of the PureWick™  
Male (System) against an established 
comparator (Stryker/ Sage PrimoFit™ )  • Capture rate following void (captured as % of 
urine captured by [CONTACT_833789], measured by [CONTACT_8497])  
Secondary  (With Hypothesis Test)   
• To assess the performance of the PureWick™  
Male (System) in patients that are unable to 
use traditional sheath style condom catheters  • Capture rate following void (captured as % of 
urine captured by [CONTACT_833789], measured by [CONTACT_8497])  
Secondary  (With out Hypothesis Test)   
• To assess participant comfort after using the 
MEC  • Overall Comfort score on a 5 -point Likert 
scale (brief questionnaire)  
• To assess ease of use by [CONTACT_833790]  • Ease of use score on a 5 -point Likert scale 
(brief questionnaire)  
 
 
[ADDRESS_1157966]-market,  crossover, single -blind , single center healthy volunteer 
study, healthy males will be randomized 1:1 to a treatment sequence using two devices UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 21 of 51 
 (PureWick™ Male External Catheter and Sage PrimoFit™ ) and followed for  [ADDRESS_1157967] inclusion/exclusio n criteria. Participants  meeting eligibility criteria will 
be assigned a treatment cohort . Participants will be divided into two cohorts . 
A. Non-morbidly obese men: BMI <40 or; 
B. Morbidly Obese men: BMI ≥40.  
Prior to any study activities, participants will be asked to review the Informed Consent  
Form  and will have an opportunity to ask the Principal Investigator (PI) any questions. 
Participants will be considered enrolled after the PI [INVESTIGATOR_833775] a signed copy of the Informed Consent  Form . 
Participants will be placed in the test area, instructed to undress, and put on a gown. The 
Health Care Professional (HCP) will complete a visual assessment of the participant’s 
pubic/ genital region to ensure that the participant is trimmed and assess the anatomy. 
Trimmers can be provided if the participant did not arrive to the site trimmed.  The HCP 
will assess for a buried penis and/or anatomical compatibility with traditional sheath style 
condom c atheters for each participant. “A buried penis refers to a normal -sized phallus 
encompassed by [CONTACT_833786], subcutaneous tissue, and/or fat in the prepubic area” causing 
a reduced visible and/or functional length of the phallus.11 
 
Void 1:  
The bed in the t est area will be set with a pre -weighed absorbent pad and a pre -weighed 
urine collection canister (with the lid).  Once the participant feels the need to void, the 
Health Care Professional (HCP) will place either the PureWick ™ MEC or the Sage 
PrimoFit™  device (depending on randomized treatment order) according to the device 
instructions  for use (IFU) and confirm the correct placement prior to the voiding epi[INVESTIGATOR_1865]. 
The participant will be placed in a semi -fowler position (head of bed elevated 
approximately 30  degrees) in a hospi[INVESTIGATOR_833776] a turning wedge 
prior to the voiding epi[INVESTIGATOR_1865]. Participants will be monitored for approximately 2 hours  
from the time of the device application , through one void. The skin needs to be assessed 
at leas t every two hours while wearing a MEC.  After the void, the pre -weighed absorbent 
pad and urine collection canister will be weighed (with the lid), and weights documented 
in the source. The Pure Wick MEC or Sage PrimoFit™  will be removed by [CONTACT_82275]. 
After r emoval, the HCP will note any signs of irritation/injury in the perineal area. Any UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 22 of 51 
 unresolved erythema (redness), erythema (swelling), bleeding, injury, or rash should be 
recorded as an Adverse Event.  The participant will be asked to complete a brief surve y to 
assess device comfort immediately after the completed void.  
The HCP will complete a brief survey to assess device ease of use for the participant just 
treated.  
Void 2:   
Participants will be asked to not void and to drink approximately 16 fluid ounces of 
liquid. When the participant feels the need to void (a second time), the HCP will confirm 
via bladder scanning  procedure that the bladder volume is ≥125mL . If the volume i s 
determined to be inadequate, the participant will be asked to drink fluids as tolerated and 
re-assessed in approximately 30 -60 minutes.  
Void 2 will be repeated per the Void 1 procedure using the 2nd device assigned per 
randomization.  
The participant wil l be asked to complete a brief survey (for the second device sequence) 
immediately following the void to assess device comfort and will then be discharged 
from the study.  
The HCP will complete a brief survey to assess device ease of use for the participant  just 
treated.  
4.2 Scientific Rationale for Study Design  
This study will assess the performance of and user experience with PureWick™ Male 
External Catheter  when compared with a marketed comparator,  Sage  PrimoFit™  Male 
External Catheter . To best mimic potent ial users of the study devices, male participants  
>18 years of age will be enrolled . Additionally, enrollment will target approximately 50% 
of the sample size of men in t wo different BMI cohorts so that potential differences based 
on anatomy can be characterized. As such, participants in this study adequately represent 
the patients who w ould use the device in the hospi[INVESTIGATOR_6885] . 
In the critical care setting  or with patient s that have limited mobility , it is commonly 
ordered for patients to be repositioned and turned on their side every two hours. A turning 
wedge is a device used by [CONTACT_2360][INVESTIGATOR_833777]. Additionally, the 
patient is commonly ordered to elevate the head of the bed.  The Primary endpoint 
provides a reliable and valid measurement of the efficacy related to the function of the 
device  by [CONTACT_833791],  including leakage, and 
dividing by [CONTACT_833792] . A higher captured rate 
constitutes a more meaningful effect.  Questionnaires using a [ADDRESS_1157968] on these UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 23 of 51 
 secondary endpoints. Furthermore, this study seeks to understand if the PureWick ™ 
MEC  will perform effec tively  in male anatomy  that is not compatible with traditional 
sheath -style condom catheters  in a controlled setting . 
 
4.2.[ADDRESS_1157969] participant in the 
study . 
 
5 STUDY POPULATION  
 
Adult male health y volunteers will be recruited for this study with a target of 50% of 
participants in each of the two BMI cohorts.  Participants  will be recruited from an existing 
pool of volunteers in a database owned by a  third -party research vendor .  Basic screening 
questions will be used to identify potential participants and f ull screening against 
inclusion/exclusion criteria will be completed on the day of enrollment .  
 
5.[ADDRESS_1157970] meet all of the 
following criteria:  
1. Adult Male Patien t ≥ 18 years old  
2. Male anatomy at time of enrollment  
3. Ability to speak and understand English  
4. Willing to comply with all study procedures in this protocol  
5. Able to i ndependently void urine  
6. Provision of signed and dated informed consent form  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 24 of 51 
 5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Urinary incontinence which does not allow the subject to spontaneously void  
2. Frequent epi[INVESTIGATOR_833778]  
3. Has Urinary Retention  
4. Has any irritation, wound, open lesion, at the application site, on the genitalia, 
perineum, or sacrum  
5. Recent surgery of the external urogenital tract, penis, or pubic area  
6. Not able to comply with study procedures independently without required 
assistance  
7. Any other condition that, i n the opi[INVESTIGATOR_871], would preclude them 
from participating in the study  
 
5.3 Lifestyle Considerations  
No restrictions are required.  
 
5.4 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized into the study. Demographic information may be 
captured for screen failures. Screen failures will not be allowed to re -screen.  
 
6 STUDY INTERVENTION (S) 
   
6.1 Investigational/Test Device  
The PureWick ™ MEC is a commercially available device.  It is a Class I , 510(k) exempt 
device.  The device is int ended for non -invasive  urine output management in male 
patients. The PureWick ™ MEC is a single -use, non-sterile  device. The IFU for the 
PureWick ™ MEC can be fo und in Appendix 1. 
 
6.2 Control Device/Standard of Care  
The Sage PrimoFit™  is a commercially available device. It is a Class I, 510(K) exempt 
device. The device is intended for non -invasive external collection of urine  for adult UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 25 of 51 
 patients with male anatomy who require urine management. The Sage  PrimoFit™  is a 
single -use, non -sterile device. The IFU for the Sage PrimoFit™  can be found in 
Appendix 2 .  
 
6.3 Ancillary Devices/Products  
Ancillary products for this study are listed below.  
• Standard suction tubing and canister s 
• BBS Revolution: Bladder Scanner + Display (PD0100002)  
• Absorbent under -pads 
• Commercially available scales  
• Clippers/trimmers  
• Wipes/towels for peri-care 
• Turning wedge ( 45-degree foam wedge)  
• PPE 
 
6.[ADDRESS_1157971] ease of use outcomes, HCPs will all be trained using standardized instructional 
videos and devi ce IFUs.  
6.5.1 Randomization  
Participants will be randomized  1:1 to one of the two  treatment sequences . 
Subjects randomized to Sequence 1 will use PureWick ™ MEC first, followed by [CONTACT_833793]-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 26 of 51 
 Sage PrimoFit™ . Subjects randomized to Sequence 2 will use Sage PrimoFit™  
first, followed by [CONTACT_833794] ™ MEC.  Randomization will be stratified by [CONTACT_32024]  
(non-morbidly  obese men: BMI <40  or morbidly obese men: BMI ≥40 ). This 
design allows for the evaluation of elements such as carryover effect, period 
effect, and sequence effect.  
The study site will receive randomization envelopes for each cohort that are 
numbered in sequential order . Within each randomization envelope, a treatment 
sequence assignment card will be enclosed. The randomization envelope s should 
be opened in sequential ord er only when all eligibility criteria are met . 
 
6.5.2 Blinding/Masking  
Complete study blinding is not feasible due to  possible HCP familiarity with the 
study d evices and visual differences between the product  packaging. As such, t his 
is a single -blind study in w hich only participants are blinded to which device is 
which. The Investigator and Sponsor will know which device the participant is 
being treated with at any given time.  
Blinding procedures will be reviewed at the time of site initiation by a Sponsor 
repre sentative. During review of the study and the informed consent process with 
participants, blinding and rationale should be discussed with the participant.  
Any communication to the study personnel placing the device as to the 
randomized treatment sequence should be done in a way as to prevent the 
participant from overhearing. Devices should be referred to  throughout the study 
period  as ‘Device A’ and ‘Device B’ rather than the marketed product name . 
Participants will remain blinded to treatment order until the study is complete.   
 
[ADDRESS_1157972] reasons for 
screening failure, as applicable.  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157973] Preparation – Prior to Arrival at Site  
Participants will be instructed to consume fluids prior to their scheduled visit and arrive 
to the site with a full bladder.  Participants will be instructed to trim the hair in their pubis / 
peri-area prior to arrival.  
 
7.[ADDRESS_1157974] the inclusion and exclusion criteria (see section 
5.1 & 5.2). Eligibility criteria requiring a physical exam ( e.g., height, weight, skin  
condition)  will be confirmed after enrollment prior to device placement. Participants who 
fail to meet eligibility criteria must not have a study device placed.  
The Investigator or their designee will explain the study to the participant, answer all of 
the participant’s questions, and obtain written informed consent before the collection of 
any study data or performance of any study procedures. A participant who signs an 
informed consent will be considered enrolled in this study.  
A unique ide ntification n umber will be given to study participants  in sequential order .  
The participant number will consist of [ADDRESS_1157975] three digits will 
designat e the participant by [CONTACT_833795] (i.e., participant number 301A101 
will be the first participant  in cohort A ; 301A102 will be the second participant  in cohort 
A, etc.).  
 
7.3 Medical History  / Baseline Assessments  
Participant demographic information, including age at time of enrollment, race , ethnicity,  
and sex, will be collected at baseline. In addition, the subject’s initials will be collected. 
Height and weight will be captured to calculate BMI.   
 
7.[ADDRESS_1157976] will be 1:[ADDRESS_1157977] with 
randomization I D and treatment sequence assignment will be enclosed. The UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157978] area will be set with clean sheets, a pre -weighed absorb ent 
pad and a pre -weighed urine collection canister.  
2. The Health Care Professional (HCP) will complete a visual assessment of the 
participant’s pubic and genital region to ensure that the participant is trimmed and 
assess the anatomy.  
a. Unless the participant arrives with their pubic hair pre -trimmed, the 
participant’s pubic hair will be clipped by [CONTACT_833796] a trained 
profes sional.  
b. The HCP will then complete a brief survey to assess for a buried penis and/or 
anatomical compatibility with traditional sheath style condom catheters for 
each participant. “A buried penis refers to a normal -sized phallus 
encompassed by [CONTACT_833786],  subcutaneous tissue, and/or fat in the prepubic 
area” causing a reduced visible and/or functional length of the phallus.[ADDRESS_1157979] either the PureWick ™ MEC or the Sage PrimoFit™  device 
(depending on randomized sequence ) according to the device IFU and confirm the 
correct placement . 
4. The participant will be placed in a semi -fowler position in the hospi[INVESTIGATOR_833779] a turning wedge. The HCP should reconfirm correct device 
placement after repositioning.  
5. The HCP will ensure the collection cannister and suction tubing are connected to wall 
suction and the suction is set to a minimum of 40mmHg continuous suction.  
6. Once setup is confirmed and the device is placed , the participant will be allowed to 
spontaneousl y void . The participant will be monitored for up to 2 hours, through one 
void.  
7. After the void, the pre -weighed absorbent pad and urine collection canister  (with lid)  
will be weighed and the weights will be documented i n the source documents.  
8. The Pure Wick  MEC or Sage PrimoFit™  will be removed by [CONTACT_833797] . 
9. After removal, the HCP will note any signs of irritation/injury in the perineal area.  
a. Any unresolved erythema (redness), erythema (swelling), bleeding, injury or 
rash must be recorded as an Adverse Event.  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157980] void using the 2nd device 
assigned  per randomization  sequence . 
13. When the participant feels the need to void, the HCP will confirm via the bladder 
scanning that the bladder volume is ≥125mL.  
a. If the volume is determined to be  inadequate, the participant will be asked to 
drink fluids as tolerated and re -assessed in approximately [ADDRESS_1157981] treated.  
16. Once the second void has completed and all survey s are completed, the participant 
can be discharged from the study site.  
 
8 PARTICIPANT DISCONTINUATION/WITHDRAWAL  
   
8.1 Discontinuation/Withdrawal  
• A participant may withdraw from the study at any time at his/her own request or  may be 
withdrawn at any time at the discretion of the investigator  or sponsor for safety, 
behavioral, compliance, or administrative reasons. This is expected to be uncommon.  
• If the participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such  a withdrawal of consent.  
• At the time of discontinuing from the study, no further assessments will be performed . 
 
 
8.[ADDRESS_1157982] to Follow -Up 
This study only has one visit thus this is not applicable.  
 
9 ADVERSE EVENTS AND DEV ICE DEFICIENCIES  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 30 of 51 
 9.1 Definitions of Events  
 
9.1.1 Adverse E vents (AEs)  
An adverse event is defined as any untoward medical occurrence, unintended 
disease or injury, or untoward clinical signs (including  abnormal laboratory 
findings) in subjects , users , or other persons, whether or not related to the  
investigational medical device and whether anticipated or unanticipated  (ISO 
[ZIP_CODE]:2020) . 
Pre-existing conditions should be considered as part of the participant ’s medical 
history and should not be reported as an AE unless there is a substantial increase 
in severity or frequency of the condition, which has not been attributed to natural 
history. Likewise, planned hospi[INVESTIGATOR_690342]/or hospi[INVESTIGATOR_833780].   Exacerbation of an existing condition should be 
reported as an AE i f the event meets the protocol definition of an AE.  
The clinical course of the event will be followed according to accepted standards 
of medical practice until the event resolves, stabilizes, or in the opi[INVESTIGATOR_684], is no longer considered c linically significant.  The Investigator must 
supply the Sponsor with information concerning the follow up and/or resolution 
of the AE.  
 
9.1.2 Serious Adverse Events (SAEs)  
A serious adverse event is defined by [CONTACT_5891] [ZIP_CODE] and/or 21 CFR 803.3 as an 
adverse event t hat:  
a. led to death;  
b. led to serious deterioration in health that resulted in life -threatening illness 
or injury, resulted in permanent impairment;  
c. required inpatient hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059], or resulted in 
medical/surgical intervention t o prevent life -threatening illness/injury or 
permanent impairment; or  
d. led to fetal distress, fetal death, or a congenital abnormality or birth defect.  
 
9.1.[ADDRESS_1157983] (ADE)  / Serious Adverse Device Effect (SADE)  
An adverse device effect is defined as any adverse event that is considered to be 
related to the use of an investigational medical device. This definition includes 
any event resulting from insufficiencies or inadequacies in the instructions for UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 31 of 51 
 use, deployment, implantation, or operation or any malfunction of the 
investigational device (study device) and includes any event that is a result of a 
user error.  
A serious adverse device effect (SADE) is defined as an ADE  that has resulted in 
any of the consequences characteristic of an SAE.  
 
9.1.4 Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  
An unanticipated ( serious) adverse device effect (UADE/[LOCATION_003]DE) is any (serious)  
adverse device effect on health or safety or any life -threatening problem or death  
caused by, or associated with, a study device, which by [CONTACT_5942], incidence,  
severity, or outcome has not been identified in the current instruction s for use 
and/or current version of the risk  analysis report, or any other unanticipated 
serious problem associated with a device  that rela tes to the rights, safety or 
welfare of participant s. 
UADEs/[LOCATION_003]DEs will be reported to  FDA as required by 21 CFR Part 812 . 
 
9.2 Severity of Adverse Events  
 
Each AE sh all be assessed for its severity, or the intensity of an event, experienced by  [CONTACT_695405].  
Severity Rating  Description  
Mild  Event, s igns, or symptoms that do not interfere with the participant ’s 
daily activity, are usually considered self -limiting, can be treated 
with non -prescription type medications , and do n ot require medical 
intervention  
Moderate  Event may interfere or cause low level inconvenience with the 
participant ’s daily activity. Requires medical intervention and/or 
treatment ; however, unlikely to require hospi[INVESTIGATOR_690344] -threatening in nature  
Severe  Event may cause significant discomfort to the participant  and/or 
interferes with the participant ’s daily activity. Requires medical 
intervention and/or treatment to preclude a permanent impairment ; 
may be lif e threatening and /or require hospi[INVESTIGATOR_833781]-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 32 of 51 
 9.3 Relationship of Adverse Event to Device(s)/Procedure  
 
Each AE will be assessed for its relationship to the study device or procedure  according 
to the following guidelines.  
A.  Assess each AE for its relationship  to the device or procedure.  
 
• Device  Related : This category should be restricted to AEs directly attributable to 
the study device used . 
• Procedure:  A procedure includes any study -related activity performed . 
 
B.  The following categories shall be used for assigning the certainty of the relatedness.  
 
Relatedness  Description   
Not Related  Event is independent of study intervention and/or evidence 
exists that the event is related to another etiology. There must 
be an alternative etiology documented by [CONTACT_833798].  
Unlikely Related  Event in which the temporal relationship to study  intervention 
makes a causal relationship improbable (e.g., the event did not 
occur within a reasonable time of the study device use) and in 
which underlying disease provides plausible explanations (e.g., 
the participant’s clinical condition other concomitant 
treatments).  
Likely Related  Event in which t here is evidence to suggest a causal 
relationship and the influence of other factors is less likely. 
The event occurs within a  reasonable time after use of the 
study device and is less likely to be attributed to concurrent 
disease.  
Related  Event in which there is clear evidence to suggest a causal 
relationship and other possible contributing factors can be 
ruled out. The event o ccurs in a plausible time relationship to 
use of the study device and cannot be explained by [CONTACT_833799].  
 
 
9.4 Reporting of Events  
 
For all adverse events, all sections of the appropriate Case Report Form (CRF) must be 
completed.  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 33 of 51 
 • All SAEs, SADEs, and/or UADEs/[LOCATION_003]DEs  must be reported to the Sponsor 
within one (1) working day of the site/investigator becoming aware of the event.    
 
• De-identified copi[INVESTIGATOR_690345] 72 hours of knowl edge, as appropriate.  
It is the responsibility of the Investigator to r eport adverse events to individual 
Institutional Review Boards (IRBs)/Ethics Committees (ECs) and/or regulatory 
authorities  according to the local regulations in each participating cou ntry. 
 
9.[ADDRESS_1157984].   Device deficiencies also include use errors and inadequate 
labeling.   This applies to: devices used to treat the participant , or devices in which the 
package was opened, but the device was not used for treatment, or devices with which 
treatment was attempt ed, but the device did not remain through the entire study 
procedure/ period.  
All mechanical failures, malfunctions, missing components , and defects of the study 
devices will be recorded  on the appropriate Case Report Form and will be promptly 
reported to t he Sponsor. The  device(s) should be returned to the Sponsor as outlined in 
the site ’s regulatory binder.  
If the device deficiency was associated with an AE, the reporting provisions for AEs,  
ADEs, SAEs, SADEs and UADEs/[LOCATION_003]DEs apply.  
Reported deficiencies will be investigated and reported under [ADDRESS_1157985] a thorough investigation.  
It is the responsibility of the Investigator to notify the IRB/EC of such device deficiencies  
in accordance with the IRB/EC and/or the Competent Authority’s local regulations.  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157986] 
important endpoints including primary and key secon dary endpoints.  
 
10.1 Overview of Stu dy Design  
This is a prospective,  randomized , crossover, single -blind , single -center  healthy  volunteer 
study conducted over 1 day with 2 voids  using the PureWick ™ Male external catheter vs. 
the comparator Sage PrimoFit™ . This study is designed to assess the performance, 
comfort,  and ease of use of the PW Male external catheter.   
A successful  hypothesis -test for the primary endpoint ( rejection of the Null Hypothesis) 
will provide evidence to support the superiority of PureWick ™ Male external catheter  
compared with standard of care, in terms of capture rate.  
 
10.[ADDRESS_1157987] at significance level of 0.05, a sample size of 44 provides  90% 
power to detect a mean paired difference in captu re rate that is half of the standard deviation of the 
paired difference. For example, if the standard deviation of paired difference in capture rate is 10%, 
a sample size of 44 provide 90% power to detect a mean paired  difference of 5%.  
 
10.3 Analysis Populatio n 
The following populations are defined:  
Population  Description  
Enrolled  All participants who sign the ICF . 
Intent -to-Treat  (ITT)  Enrolled and randomized participants . 
Per-Protocol  ITT subjects who are without major protocol deviation.  
ITT Subpopulation  ITT subjects who are deemed unable to use traditional sheath 
style condom catheters.  
 
ITT p opulation  will be used for the primary endpoint  analysis . ITT subpopulation  will be 
used for the s econdary endpoint with hypothesis test . Per-protocol analyses may be 
performed as a sensitivity analysis.  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 35 of 51 
  
10.4 General Considerations  
 
10.4.1  Handling of Missing Data  
Endpoint data may be missing due to reasons including withdrawal of consent, 
investigator’s decision, or loss to follow -up. It is important to minimize m issing 
data and always record the reason for missing.  Analyses are primarily based on 
evaluable data. If there is any indication that missing is related to study endpoints, 
sensitivity analyses may be carried out to assess the impact of missing data.  
  
10.4.[ADDRESS_1157988] for the secondary endpoint is considered exploratory.   
 
10.5 Primary Endpoint(s)  
 
Capture rate is defined by : 
 
[CONTACT_833800] / (captured urine weight + leaked urine weight)  
 
The primary endpoint will be evaluated against the following hypothe ses: 
 
H0: Capture rate of PureWick™ Male (system) = Capture rate of established 
comparator (Stryker/ Sage PrimoFi t™) 
H1: Capture rate of PureWick™ Male (system) ≠ Capture rate of established 
comparator (Stryker/ Sage PrimoFit™ ) UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157989] the hypotheses and p -value will be derived. A 
p-value < 0.05, combined with a capture rate in favor of PureWick™, indicates that 
PureWick™ is superior to PrimoFit™  in terms of urine capture.  
An exploratory analysis will be performed us ing regression, where subject may be  
included as the random effect, and period , sequence,  treatment may be  included as fixed 
effect s.  
 
10.6 Secondary Endpoint(s)  
Secondary Endpoint with Hypothesis Test  
 
If primary endpoint passes the hypothesis test, the same hypothesis test will be performed 
in the subgroup population of ITT participants  who are unable to use traditional sheath 
style condom catheters. Using the fix -sequence method, the overall type I error is 
controlled since the test of this secondary endpoin t is conditional on the success of the test 
of the primary endpoint.   
 
Secondary Endpoints  without Hypothesis Test 
• Overall Comfort score on a 5 -point Likert scale (brief questionnaire).  
• Ease of use by [CONTACT_833801] (brief questionnaire).  
 
10.[ADDRESS_1157990] MAINTENANCE  
 
11.1 Case Report Forms  
The Investigator is responsible for ensuring the completeness and accuracy of all study  
documentation.  
All required clinical data will be collected /documented in sponsor -provided web-based 
electronic Case Report Forms ( eCRFs).  The Investigator may delegate eCRF completion 
to study personnel. However, the Sponsor must be apprised in writing of the name [CONTACT_833809]. The Investigator or designee is obligated to UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157991] be 
traceable to original source documents. Modificatio n of the eCRFs will only be made if 
deemed necessary by [CONTACT_1052]/or the appropriate regulatory body.  
Site numbers and  participant  numbers will be used to track participant  information 
throughout the study.   Participant personal information will be d e-identified. Site 
numbers and participant numbers will be used to track participant  information throughout 
the study.  
 
11.[ADDRESS_1157992] of data, such as for subjective  data (e.g., pain scales, questionnaires) , these data 
may be recorded directly on the eCRF (s) and the e CRF is then considered to be the 
source.    
 
11.3 Data Management  
Data management is the responsibility of the Sponsor.   Data from completed eCRFs will 
be managed in a secured, controlled database . A Da ta Management Plan (DMP) will be 
developed that outlines the procedures used for data review, database cleaning and 
issuing/resolving data queries. Procedures for validations and data storage will also be 
contained within the DMP.   Observation data will be  collected prospectively at the time 
of each urine output monitoring event. As such, any missing data or inconsistent data 
cannot be retrieved from an alternate source. Particular care must be taken to ensure that 
all data are recorded in a clear and compl ete manner.  
 
11.[ADDRESS_1157993] Retention  
The Investigator shall retain all study records for a minimum of two (2) years after the  
later of the following two dates: the date on which the study is terminated/completed or  
the date that the records are no longer required  for purposes of supporting a pre -market  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157994] development protocol  (21 
CFR Part 812.140 ). The  data for some of these records may be available in computerized 
form but the final  responsibility for maintaining study records remains with the 
Investigator.  
The Investigator may withdraw from the responsibility to maintain records for the period  
required by [CONTACT_833802]. Notice of a transfer shall be given to the Sponsor and  
FDA , if applicable,  not later than ten (10) working days after the transfer occurs . 
 
[ADDRESS_1157995] 
obtained written IRB/EC approval (as required) for participation in this study, who have 
completed all required study documentation, and who have been qualified by [CONTACT_429].  Investigators must maintain control over all study products, and ensure they are 
used in accordance with this protocol.  Failure to do so may result in the Sponsor 
suspending or terminating the study at the Investigator’s site.  
  
The Investigator will ensure that study products are only dispense d to participant s (or 
used for specimens) properly enrolled in the study. The Investigator must maintain 
records of receipt, disposition, return and/or destruction of all study products. All 
investigational study products released to the site must be accou nted for at the unit level 
prior to study close out, regardless of disposition.  The S ponsor -Monitor will regularly 
review all records regarding study product accountability.  
The Sponsor will maintain records that document the shipment, receipt, dispositio n, 
return and/or destruction of study products.  
 
12.[ADDRESS_1157996] operating procedures and the 
study -specific Monito ring Plan.  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 39 of 51 
 Prior to study start, a study initiation visit  (SIV)  will be conducted to review with the 
Investigator(s) and staff the provisions and proper  conduct of this study. This visit will 
include a detailed review of this protocol,  verification that all necessary documents are on 
file at the investigational site and  confirmation of IRB/EC approvals.  
During the study, routine monitoring visits  (RMV s) will be conducted to assure the site 
continues to adhere to the protocol, the investigator agreement, a nd regulations regarding 
conduct of clinical studies.  The Sponsor -Monitor will confirm that the ICF to be used is 
the version  approved by [CONTACT_1201]/EC, confirm the applicable national privacy laws have 
been  followed , verify that  all necessary documents are on file at the investigational site 
and confirm that there are  provisions to continue and maintain all documents and records 
throughout the study as  required by [CONTACT_5279]. These monitoring visit s will 
assess continued protocol  compliance, adeq uate participant  enrollment, accurate data  
reporting,  monitoring of participant  safety through identification and/or review of any 
device -related  AEs, UADEs, or SAEs, device accountability, continued maintenance,  and 
calibration of  study -specific equipment  (if applicable), and continued IRB/EC acceptance 
of the study.  
At the completion of the study, the Sponsor -Monitor  will conduct a final close -out visi t 
or COV . The  purpose of this visit may include but is not limited to collecting all 
outstanding study data documents, confirming that the Investigator’s files are accurate 
and complete, reviewing  the record retention requirements with the Investigator, 
providing for the return of unused  devices to the Sponsor, reviewing records which 
account for device shi pments and  ensuring that all applicable requirements for closure of 
the study are met.  
 
12.[ADDRESS_1157997] agree to the inspection of all study 
related records and give the auditor/inspector direct access to source documents for 
verification of data on CRFs.  The participant ’s anonymity  must be ensured,  and data 
checked during the audit must remain confidential.  
As soon as the Investigator is aware of an upcoming inspection/audit by [CONTACT_36296], he/she will promptly inform the Sponsor .  As agreed with the Investigator, 
Sponsor  personnel may be present at the site during the inspection.  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1157998] the  life or physical well -being of a participant , protocol 
deviations are not permitted.  The S ponsor and the investigational site’s IRB/EC must be 
notified immediately if an emergency situation arises in which the safety of a participant  
may require immediat e intervention different than that defined in the protocol.  This must 
be followed by [CONTACT_695406], 
within five (5) working days from the date of the emergency action  in accordance with 
the governing  IRB/EC’s requirement.  
It is the Investigator’s responsibility to ensure that there are no deviations from the  
Protocol. Except in an emer gency , when a protocol deviation is planned or anticipated, 
the Sponsor should be contact[CONTACT_291444].  Any and all  deviations must be recorded 
on the appropriate CRF regardless of whether medically justifiable  or sponsor approved .  
Upon evaluation by [CONTACT_1034], actions may be required to prevent additional 
deviations, such as retraining of the site, implementation of additional site procedures, 
and more frequent monitoring.  If these steps fail, more serious measures, up to and 
including termination of enrollment at the site.  
 
 
[ADDRESS_1157999]  
appropriate research experience and infrastructure to ensure adherence to this protocol  
and enrollment of sufficient numbers of evaluable particip ants. The curriculum vitae 
(CV) of  the Investigator(s), Sub -Investigator(s) and Study Coordinator(s) will be 
maintained in  the Sponsor’s files as documentation of qualification by [CONTACT_833803].  
The Principal Investigator [INVESTIGATOR_833782], 
agreeing to  comply with all applicable regulations and the requirements of this study  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page [ADDRESS_1158000] training  will be  
provided by [CONTACT_690377]. Additional 
study staff  (e.g., Sub-Investigator(s) ) will also require device training provided from the 
Sponsor or pro ctoring  by [CONTACT_978]. All training will be documented and filed at the 
investigational site and with  the Sponsor.  
 
13.3 Required Documents  
 
An Investigator may not screen or enroll participant s until authorized to do so by [CONTACT_55688]. At a minimum, the following documentation should be received by [CONTACT_833804]:  
• Fully executed Non-disclosure Agreement (NDA) between PI /site and Sponsor ; 
• CVs, signed and dated within 2 years of study start for the PI [INVESTIGATOR_34511] -
Investigator(s) ; 
• CVs for Study Coordinator(s);  
• Signed CSA by [CONTACT_976] /site (or designee);  
• Signed Investigator Agreement Page  by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Signed Financial Disclosure Statement by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Completed and Signed Training Log  by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Study Personnel Identification list;  
• Written approval from the IRB/EC of both the protocol and ICF, and any other  
applicable protocol specific material; and  
• IRB/EC Membership List, Assurance of Compliance Form, or equivalent.  
 
13.4 Publication Policy  
 
The sponsor believes that results of applicable clinical studies  should be published in 
peer-reviewed literature in a timely, accurate, complete and balanced manner, regardless 
of study outcomes , whenever possible .  As such, at the conclusion of this study, an article 
may be prepared for publication in a reputable  scientific journal.   Formal presentation (s) 
or publication (s) of data collected from this study will be considered as a joint publication UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 42 of 51 
 by [CONTACT_093](s) and the appropriate perso nnel of the Sponsor . Authorship will be 
based on generally accepted criteria of the ICMJE (International Committee of Medical 
Journal Editors) and  determined by [CONTACT_11402].  
The publication of the principal results from any single -center experience wi thin the 
study is not allowed until the preparation and publication of the multicenter results. 
Exceptions to this rule require the prior approval of the Sponsor. The analysis of other 
pre-specified and non -pre-specified endpoints will be performed by [CONTACT_152486]. Such analyses, as well as other proposed investigations or manuscripts will 
require the approval of the Sponsor.  
 
13.[ADDRESS_1158001] of 
2007 (FDAAA), t he Sponsor will register this study studies and disclose study results in a 
publicly accessible database (i.e., ClinicalTrials.gov). This study will be registered no 
later than [ADDRESS_1158002] participant visit . 
 
13.6 Termination of Study  
The Sponsor reserves the right to suspend enrollment or terminate the study at any time  
for any reason.  Th e Sponsor may suspend enrollment or terminate the study at a  specific 
investi gational site for reasons including, but not limited to, inadequate data  collection, 
low participant  enrollment rate, achievement of the total enrollment, conditions  imposed 
by [CONTACT_3488]/EC and/or non -compliance with this protocol or other  clinical  
research requirements. Written notice will be submitted to the Investigator in  advance of 
such termination.  
In the event of study suspension or termination, the Sponsor will send a report outlining  
the circumstances to the IRB/EC, and all Investigators an d Regulatory Authorities as  
required by [CONTACT_5151].  
 
14 ETHICAL AND REGULATORY CONSIDERATIONS  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 43 of 51 
 14.1 IRB/EC Approval  
Investigators or designees must submit the study protocol, Informed Consent Form (if 
applicable) , and all other  locally  required documentation to an appropriate  IRB/EC and 
obtain study -specific written approval  (favorable opi[INVESTIGATOR_1649])  before being allowed to 
participate in the study. Before commencement of the  study, the Investigator or designee 
must provide the Sponsor with written documentation  of suc h approval.  The IRB/EC 
must give written renewal of the original approval at  least annually to continue the study. 
A copy of the written renewal must be provided to  the Sponsor.  
The IRB/EC will be notified of any amendments to the protocol, as well as pos sible 
associated information and consent form changes, where applicable, and written approval 
(favorable opi[INVESTIGATOR_1649]) will be obtained prior to implementation, as applicable.  
The Investigator or designee is responsible for fulfilling any conditions of approval  
imposed by [CONTACT_1201]/EC, such as regular safety reporting, study  timing, etc. The 
Investigator or designee will provide the Sponsor with copi[INVESTIGATOR_695383].  
 
14.2 Informed Consent and Confidentiality  
Prior to any study procedure, the Investigator (or designe e) must explain to each 
participant  in layman’s terms, the nature of the study, its purpose, expected duration, and 
the risks  and benefits of study participation. Also, participant  will be informed of uses 
and disclosures of their medical information for research purposes, and their rights to 
access  information about them. All applicable national privacy laws (e.g., HIPAA 
requirements  in the U.S.) will be followed in this study. The partic ipants  must be 
informed of their right to  withdraw from the study at  any time and for any reason without 
sanction, penalty, or loss  of benefits to which they are otherwise entitled, and that  
withdrawal from the study will  not jeopardize their future medical care. Participants  will 
be informed of their right to new  informat ion and/or findings relating to the clinical 
study, and the process by [CONTACT_690380]. After this 
explanation, given sufficient time to decide  whether to participate, before any study 
procedure is conducted, and before entering th e study, the participant  must voluntarily 
provide consent in accordance with 21 CFR Parts 50  and 56 and ISO [ZIP_CODE]: 2020(E). The 
participant  will receive a copy of his/her signed ICF.  
 
14.2.[ADDRESS_1158003] be strictly held in trus t by [CONTACT_737], study  
staff, and the Sponsor.  Participant confidentiality and anonymity will be UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 44 of 51 
 maintained by [CONTACT_690381], documentation, or clinical 
samples submitted to the Sponsor . 
Any data collected meeting the definition of protected/confidential health 
information or personal identifying information w ill be collected and maintained 
using the designated authorizations and following privacy procedures as specified 
in the applicable health authority regulations.  
The Sponsor -Monitor, authorized repr esentatives of the sponsor, and/or applicable 
Health Authorities may inspect all documents and records required to be 
maintained by [CONTACT_737].  The Investigator/ Site will permit acces s to such 
records.  
 
14.3 Regulatory Status  
The PureWick™ Male External Catheter is a Class I, 510(k) exempt device currently 
marketed in the [LOCATION_002] and will be evaluated for its approved indication. The 
comparator device, Sage PrimoFit™ , is also a comme rcially available device which is 
Class I, 510(K) exempt . Institutional Review Board (IRB) submission of this study plan 
along with IRB study approval or waiver is required.  
 
14.4 Statement of Compliance  
This clinical investigation will be conducted in complia nce with the protocol and  
following regulatory requirements:  
• 21 CFR 50, 54, 56 and 812;  
• 21 CFR  812.28(a)(1) (Good Clinical Practice) ; 
• ISO14155:2020 (Good Clinical Practice);  
• Ethical principles of the Declaration of Helsinki , in its current revision; and  
• Applicable sections of the national laws and regulations.  
 
The clinical investigation will not commence at a clinical site until approval ( favorable 
opi[INVESTIGATOR_1649] ) from the respective IRB/EC has been received. All additional requirements 
imposed by  [CONTACT_1201]/EC(s)  will be followed. Involvement of the national competent 
authorities  (e.g., by [INVESTIGATOR_520383], seeking authorization ) will be accomplished as required 
by [CONTACT_695410].  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 45 of 51 
 15 REFERENCES  
1. Beeckman D, Van Damme N, Schoonhoven L, Van Lancker A, Kottne r J et al. (2016) 
Interventions for preventing and treating incontinence -associated dermatitis in adults. 
Cochrane Database Syst Rev 11 CD011627.  
2. Bender JK, Faergemann J, Skold M (2017) Skin Health Connected to the Use of 
Absorbent Hygiene Products: A Rev iew. Dermatol Ther (Heidelb)  
3. Beeckman D, Van Lancker A, Van Hecke A, Verhaeghe S (2014 ) A systematic review 
and meta -analysis of incontinence -associated dermatitis, incontinence, and moisture as 
risk factors for pressure ulcer development.  Res Nurs Healt h 37 (3): 204 -218.  
4. Beeckman D, et al. (2015) Proceedings of the Global IAD Expert Panel. 
Incontinenceassociated dermatitis: moving prevention forward. Wounds International 
Available to download from www. woundsinternational.com . 
5. Chant C, Smith OM, Marshall JC, Friedrich JO (2011) Relationship of catheter -
associated urinary tract infection to mortality and length of stay in critically ill patients: a 
systematic review and meta -analysis of observational stud ies.  Crit Care Med 39 (5): 
1167 -1173.  
6. Tandogdu Z, Bartoletti R, Cai T, Cek M, Grabe M et al. (2016) Antimicrobial resistance 
in urosepsis: outcomes from the multinational, multicenter global prevalence of 
infections in urology (GPIU) study 2003 -2013. Worl d J Urol 34 (8): 1193 -1200.  
7. CATHETER, U. C. M. E. (2008) Good Practice in Healthcare: Male External Catheters, 
Condom Catheter Urinary Sheath. EAUN MEC Guidelines  
8. Staniorski, C. J., & Rusilko, P. J. (2021). The concealed morbidity of buried penis: a 
narrat ive review of our progress in understanding adult -acquired buried penis as a 
surgical condition. Translational Andrology and Urology, 10(6), 2536.  
9. Mirastschijski, U. (2018). Classification and treatment of the adult buried penis. Annals 
of Plastic Surgery , 80(6), 653 -659. 
10. Fuller, T. W., Theisen, K. M., Shah, A., & Rusilko, P. J. (2018). Surgical management of 
adult acquired buried penis. Current Urology Reports, 19, 1 -8. 
11. 11. Ho, T. S., & Gelman, J. (2018). Evaluation and management of adult acquired buried 
penis.  Translational Andrology and Urology , 7(4), 618.  
 
 
 
 
  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 46 of 51 
 16 APPENDICES  
16.1 Appendix 1: PureWick ™ Male External Catheter  Instructions for Use (IFU)  
 
UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 47 of 51 
  
UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 48 of 51 
 16.2 Appendix 2: Sage PrimoFit™  Instructions for Use (IFU)  
 
UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 49 of 51 
  
UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022   CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 50 of 51 
  
16.3 Appendix 3: Participant Comfort Scale  Survey  
To be completed by [CONTACT_833805] (total of 2 per participant).  
Participant Number:  Void # (Void 1 or Void 2)  
Now that you have experienced the use of the device as well as voiding with the device in place, 
please answer the following q uestions  considering the use of the current male external catheter . 
1.  On a scale of 1 to 5 where 1 is very uncomfortable and 5 is very comfortable, how comfortable 
was the placement  of the male external catheter ? 
1 
Very 
uncomfortable  2 
Uncomfortable  3 
Neither 
comfortable  nor 
uncomfortable  4 
Comfortable  5 
Very 
Comfortable  
 
2.  On a scale of 1 to 5 where 1 is very uncomfortable and 5 is very comfortable, how comfortable 
was the device while you were voiding ? 
1 
Very 
uncomfortable  2 
Uncomfortable  3 
Neither 
comfortable  nor 
uncomfortable  4 
Comfortable  5 
Very 
Comfortable  
3.  On a scale of 1 to 5 where 1 is very uncomfortable and 5 is very comfortable, how comfortable 
was the removal  of the male external catheter ? 
1 
Very 
uncomfortable  2 
Uncomfortable  3 
Neither 
comfortable  nor 
uncomfortable  4 
Comfortable  5 
Very 
Comfortable  
4.  On a scale of 1 to 5 where 1 is very unlikely and 5 is very likely, how likely would you be to 
recommend the male external catheter  to one of your loved ones?  
1 
Very Unlikely  2 
Unlikely  3 
Neither Likely nor 
Unlikely  4 
Likely  5 
Very Likely  
 UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0
Protocol Number:  UCC -23AC022  CONFIDENTIAL  
Version: 1.0  
Date: 16May2023  
Page 51 of 51 16.4  Appendix 4: Professional Ease of Use Questionnaire  
To be completed by [CONTACT_833806] . 
HCP:  Void # : 
Now that you have experienced the application and removal of the device for this participant, 
please answer the following questions using your professional opi[INVESTIGATOR_833783].  
On a scale of 1 to 5 where 1 is very difficult and 5 is very easy, how easy was 
the placement  of the device?  
1 
Very difficult  2 
Somewhat 
difficult  3 
Average 
difficulty  4 
Somewhat easy  5 
Very easy  
On a scale of 1 to 5 where 1 is very difficult and 5 is very easy, how easy was the  removal  of 
the device?  
1 
Very difficult  2 
Somewhat 
difficult  3 
Average  
difficulty  4 
Somewhat easy  5 
Very easy  UCC-23AC022-- Protocol | VV-TMF-270487
Downloaded on 14 Jun 2024
System Version Number 1.0